388870.Kq
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research activities.
Business. The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research activities.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research activities.
The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 25,511,878,170, significantly exceeding its total liabilities of KRW 15,942,556,870. The liquidity FPT (free cash flow to total liabilities) is not explicitly provided, but the current ratio of 18.96 indicates a robust ability to meet short-term obligations. The price-to-book ratio of 6.4 and price-to-tangible-book ratio of 6.4 suggest that the market is valuing the company's equity at a premium relative to its book value.
Profitability metrics are negative, with a return on equity (ROE) of -0.7724 and a return on assets (ROA) of -0.3601, indicating that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income is negative at KRW -11,507,092,760, and the net income is also negative at KRW -10,756,653,750, reflecting ongoing losses. These figures are below the industry median for profitability metrics, suggesting underperformance relative to peers.
The company's revenue is reported as zero, which may indicate a lack of disclosed revenue sources or a reporting anomaly. There is no information provided on segments or geographic exposure, making it difficult to assess revenue concentration or diversification. The absence of revenue data also complicates the evaluation of the company's growth trajectory and market position.
The company's outlook for the current fiscal year is not explicitly provided, but the negative operating and net income figures suggest a challenging financial environment. The free cash flow is negative at KRW -9,961,893,890, and the operating cash flow is also negative at KRW -8,347,267,820, indicating that the company is not generating sufficient cash from operations to sustain its activities. The capital expenditure of KRW -42,724,140 suggests minimal investment in long-term assets, which may limit future growth potential.
The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The debt-to-equity ratio of 0.57 suggests a moderate level of leverage, and the low dilution potential implies that the company is not likely to issue additional shares in the near term to raise capital. The absence of dilution flags and the low dilution potential are positive indicators for shareholders.
Recent events, including filings and transcripts, do not show any significant developments that would impact the company's financial position or strategic direction. The company's financial statements do not indicate any major legal, regulatory, or operational issues that could affect its future performance.
- The company has a strong liquidity position with a current ratio of 18.96, indicating a robust ability to meet short-term obligations.
- Profitability metrics are negative, with a return on equity of -0.7724 and a return on assets of -0.3601, suggesting underperformance relative to industry standards.
- The company's revenue is reported as zero, which may indicate a lack of disclosed revenue sources or a reporting anomaly.
- The company is not generating sufficient cash from operations to sustain its activities, with a negative free cash flow of KRW -9,961,893,890.
- The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected.
- The company's capital expenditure is minimal, which may limit future growth potential.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- 388870.KQ Market data — financials · 2026-05-26